BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)

The Department of Biomedical Advanced Research and Development Authority (BARDA) – Division of Research, Innovation Ventures (DRIVe) is issuing EZBAA‑22‑100‑SOL‑00003 amendments that update closing dates, reopen, pause, or revise several Areas of Interest (AOIs), most notably AOI 19 “Healing Lungs.” All responsible sources with an active SAM.gov registration may submit abstract proposals; non‑conforming submissions will be deemed non‑responsive. Proposals must be product‑driven, include a defined intended use, and present a translational clinical validation plan. Required content includes a narrative of preliminary data (with supporting figures in a single attachment), a detailed technical approach describing how the solution works, its Technology Readiness Level(s), quantitative R&D deliverables and milestones, performance specifications (e.g., analytes, limits of detection, algorithm accuracy), and plans for pre‑clinical/clinical studies, regulatory strategy, and commercialization timeline. Respondents must also demonstrate the ability to analyze data from diverse, including immunocompromised, populations and address any populations not amenable to the assay. Failure to meet these specific solicitation and special‑instruction requirements will result in a non‑responsive determination.

Notice ID

42afa51fe02949309a6bdd4ce111f1c4

Solicitation Number

DRIVeEZBAA22100SOL00003

NAICS Code

541714

Classification Code

AN13